US20060275357A1 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
US20060275357A1
US20060275357A1 US10/552,005 US55200505A US2006275357A1 US 20060275357 A1 US20060275357 A1 US 20060275357A1 US 55200505 A US55200505 A US 55200505A US 2006275357 A1 US2006275357 A1 US 2006275357A1
Authority
US
United States
Prior art keywords
alkyl
substituted
halogen
mannitol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/552,005
Other languages
English (en)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Colleen Ruegger
Alan Royce
Masaki Sasaki
Tokuhiro Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060275357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/552,005 priority Critical patent/US20060275357A1/en
Application filed by Individual filed Critical Individual
Publication of US20060275357A1 publication Critical patent/US20060275357A1/en
Priority to US12/189,323 priority patent/US8324283B2/en
Priority to US12/191,098 priority patent/US20090203798A1/en
Priority to US12/987,726 priority patent/US20110105620A1/en
Priority to US13/721,278 priority patent/US20130108675A1/en
Priority to US14/027,943 priority patent/US20140011885A1/en
Priority to US14/285,808 priority patent/US20140255497A1/en
Priority to US15/634,579 priority patent/US20170290787A1/en
Priority to US16/274,357 priority patent/US20190175527A1/en
Priority to US16/839,703 priority patent/US20200237690A1/en
Priority to US17/501,173 priority patent/US20220031609A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to pharmaceutical compositions comprising a sphingosine-1 phosphate receptor agonist.
  • Sphingosine-1 phosphate (hereinafter “S1P”) is a natural serum lipid.
  • S1P receptors namely S1P1 to S1P8.
  • S1P receptor agonists have accelerating lymphocyte homing properties.
  • S1P receptor agonists are immunomodulating compounds which elicit a lymphopenia resulting from a re-distribution, preferably reversible, of lymphocytes from circulation to secondary lymphatic tissue, evoking a generalized immunosuppression.
  • Naive cells are sequestered, CD4 and CD8 T-cells and B-cells from the blood are stimulated to migrate into lymph nodes (LN) and Peyer's patches (PP), and thus infiltration of cells into transplanted organs is inhibited.
  • LN lymph nodes
  • PP Peyer's patches
  • S1P receptor agonists show structural similarities, which result in related problems in providing a suitable formulation.
  • an S1P receptor agonist containing formulation which is well-adapted for oral administration in a solid form, e.g. as a tablet or capsule.
  • the present invention provides a solid pharmaceutical composition suitable for oral administration, comprising a S1P receptor agonist and a sugar alcohol.
  • compositions comprising a sugar alcohol provide formulations which are particularly well suited to the oral administration of S1P receptor agonists.
  • the compositions provide a convenient means of systemic administration of S1P receptor agonists, do not suffer from the disadvantages of liquid formulations for injection or oral use, and have good physicochemical and storage properties.
  • the compositions of the present invention may show a high level of uniformity in the distribution of the S1P receptor agonist throughout the composition, as well as high stability.
  • the compositions of the invention may be manufactured on high speed automated equipment, and thus do not require hand encapsulation.
  • S1P receptor agonists are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives.
  • S1P receptor agonists are, for example:
  • a S1P receptor agonist for use in a combination of the invention may also be a selective S1P1 receptor, e.g. a compound which possesses a selectivity for the S1P1 receptor over the S1P3 receptor of at least 20 fold, e.g. 100, 500, 1000 or 2000 fold, as measured by the ratio of EC50 for the S1P1 receptor to the EC50 for the S1P3 receptor as evaluated in a 35S-GTP ⁇ S binding assay, said compound having an EC50 for binding to the S1P1 receptor of 100 nM or less as evaluated by the 35S-GTP ⁇ S binding assay.
  • Representative S1P1 receptor agonists are e.g. the compounds listed in WO 03/061567, the contents of which being incorporated herein by reference, for instance a compound of formula
  • Acyl may be a residue R y —CO— wherein R y is C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenyl-C 1-4 alkyl. Unless otherwise stated, alkyl, alkoxy, alkenyl or alkynyl may be straight or branched.
  • the carbon chain as R 1 is substituted, it is preferably substituted by halogen, nitro, amino, hydroxy or carboxy.
  • the carbon chain is interrupted by an optionally substituted phenylene, the carbon chain is preferably unsubstituted.
  • the phenylene moiety is substituted, it is preferably substituted by halogen, nitro, amino, methoxy, hydroxy or carboxy.
  • Preferred compounds of formula I are those wherein R 1 is C 13-20 alkyl, optionally substituted by nitro, halogen, amino, hydroxy or carboxy, and, more preferably those wherein R 1 is phenylalkyl substituted by C 6-14 -alkyl chain optionally substituted by halogen and the alkyl moiety is a C 1-6 alkyl optionally substituted by hydroxy. More preferably, R 1 is phenyl-C 1-6 alkyl substituted on the phenyl by a straight or branched, preferably straight, C 6-14 alkyl chain. The C 6-14 alkyl chain may be in ortho, meta or para, preferably in para.
  • each of R 2 to R 5 is H.
  • a preferred compound of formula I is 2-amino-2-tetradecyl-1,3propanediol.
  • a particularly preferred S1P receptor agonist of formula I is FTY720, i.e. 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form (referred to hereinafter as Compound A), e.g. the hydrochloride, as shown:
  • a preferred compound of formula II is the one wherein each of R′ 2 to R′ 5 is H and m is 4, i.e. 2-amino-2- ⁇ 2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl ⁇ propane-1,3-diol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound B), e.g the hydrochloride.
  • a preferred compound of formula III is the one wherein W is CH 3 , each of R′′ 1 to R′′ 3 is H, Z 2 is ethylene, X is heptyloxy and Y is H, i.e. 2-amino-4-(4-heptyloxyphenyl)-2-methyl-butanol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound C), e.g. the hydrochloride.
  • Compound C e.g. the hydrochloride.
  • the R-enantiomer is particularly preferred.
  • a preferred compound of formula IVa is the FTY720-phosphate (R 2a , is H, R 3a is OH, X a is O, R 1a and R 1b are OH).
  • a preferred compound of formula IVb is the Compound C-phosphate (R 2a is H, R 3b is OH, X a is O, R 1a and R 1b are OH, Y a is O and R 4a is heptyl),
  • a preferred compound of formula V is Compound B-phosphate.
  • a preferred compound of formula V is phosphoric acid mono-[(R)-2-amino-2-methyl-4-(4-pentyloxy-phenyl)-butyl]ester.
  • a preferred compound of formula VIII is (2R)-2-amino-4-[3-(4-cyclohexyloxybutyl) benzo[b]thien-6-yl]-2-methylbutan-1-ol.
  • Examples of pharmaceutically acceptable salts of the compounds of formulae I to XIII include salts with inorganic acids, such as hydrochloride, hydrobromide and sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate and benzenesulfonate salts, or, when appropriate, salts with metals, such as sodium, potassium, calcium and aluminium, salts with amines, such as triethylamine and salts with dibasic amino acids, such as lysine.
  • the compounds and salts of the present invention encompass hydrate and solvate forms.
  • Binding to S1P receptors can be determined according to the following assays.
  • SIP receptors and G i proteins are cloned, and equal amounts of 4 cDNAs for the EDG receptor, G i - ⁇ , G i - ⁇ and G i - ⁇ are mixed and used to transfect monolayers of HEK293 cells using the calcium phosphate precipitate method (M. Wigler et al., Cell. 1977;11;223 and D S. Im et al., Mol. Pharmacol. 2000;57;753). Briefly, a DNA mixture containing 25 ⁇ g of DNA and 0.25 M CaCl 2 is added to HEPES-buffered 2 mM Na 2 HPO 4 .
  • Subconfluent monolayers of HEK293 cells are poisoned with 25 mM chloroquine, and the DNA precipitate is then applied to the cells. After 4 h, the monolayers are washed with phosphate-buffered saline and refed media (90% 1:1 Dulbecco's modified essential media (DMEM):F-12+10% fetal bovine serum). The cells are harvested 48-72 h after addition of the DNA by scraping in HME buffer (in mM: 20 HEPES, 5 MgCl 2 , 1 EDTA, pH 7.4) containing 10% sucrose on ice, and disrupted using a Dounce homogenizer.
  • HME buffer in mM: 20 HEPES, 5 MgCl 2 , 1 EDTA, pH 7.4
  • GTP ⁇ S binding experiments are performed as described by D S. Im et al., Mol. Pharmacol. 2000; 57:753.
  • Ligand-mediated GTP ⁇ S binding to G-proteins is measured in GTP binding buffer (in mM: 50 HEPES, 100 NaCl, 10 MgCl 2 , pH 7.5) using 25 ⁇ g of a membrane preparation from transiently transfected HEK293 cells.
  • Ligand is added to membranes in the presence of 10 ⁇ M GDP and 0.1 nM [ 35 S]GTP ⁇ S (1200 Ci/mmol) and incubated at 30° C. for 30 min.
  • Bound GTP ⁇ S is separated from unbound using the Brandel harvester (Gaithersburg, Md.) and counted with a liquid scintillation counter.
  • composition of the invention preferably contains 0.01 to 20% by weight of S1P receptor agonists, more preferably 0.1 to 10%, e.g. 0.5 to 5% by weight, based on the total weight of the composition.
  • the sugar alcohol may act as a diluent, carrier, filler or bulking agent, and may suitably be mannitol, maltitol, inositol, xylitol or lactitol, preferably a substantially non-hygroscopic sugar alcohol, e.g. mannitol (D-mannitol).
  • a single sugar alcohol may be used, or a mixture of two or more sugar alcohols, e.g a mixture of mannitol and xylitol, e.g. in a ratio of 1:1 to 4:1.
  • the sugar alcohol is prepared from a spray-dried composition, e.g. mannitol composition, having a high specific surface area.
  • a spray-dried composition e.g. mannitol composition
  • the use of this type of mannitol composition may assist in promoting uniform distribution of the S1P receptor agonist throughout the mannitol in the compositon.
  • a higher surface area may be achieved by providing a sugar alcohol, e.g. mannitol, preparation consisting of particles having a smaller mean size and/or a rougher surface on each particle.
  • the use of a spray-dried sugar alcohol, e.g. mannitol, e.g. with a mean particle size of 300 ⁇ m or less, has also been found to improve compressibility and hardness of tablets formed from the composition.
  • the single point surface area of the sugar alcohol preparation is 1 to 7 m 2 /g, e.g. 2 to 6 m 2 /g or 3 to 5 m 2 /g.
  • the mannitol preparation may suitably have a mean particle size of 100 to 300 ⁇ m, e.g. 150 to 250 ⁇ m and a bulk density of 0.4 to 0.6 g/mL, e.g. 0.45 to 0.55 g/mL.
  • a suitable high surface area mannitol is Parteck M200, available commercially from E. Merck.
  • the composition preferably contains 75 to 99.99% by weight of the sugar alcohol, more preferably 85 to 99.9%, e.g 90 to 99.5% by weight, based on the total weight of the composition.
  • the composition preferably further comprises a lubricant.
  • Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, zinc stearate, glyceryl palmitostearate, sodium stearyl fumarate, canola oil, hydrogenated vegetable oil such as hydrogenated castor oil (e.g. Cutina® or Lubriwax® 101), mineral oil, sodium lauryl sulfate, magnesium oxide, colloidal silicon dioxide, silicone fluid, polyethylene glycol, polyvinyl alcohol, sodium benzoate, talc, poloxamer, or a mixture of any of the above.
  • the lubricant comprises magnesium stearate, hydrogenated castor oil or mineral oil. Colloidal silicon dioxide and polyethylene glycol are less preferred as the lubricant.
  • the composition preferably contains 0.01 to 5% by weight of the lubricant, more preferably 1 to 3% by weight, e.g. about 2% by weight, based on the total weight of the composition.
  • the composition may comprise one or more further excipients such as carriers, binders or diluents.
  • the composition may comprise microcrystalline cellulose (e.g. Avicel®), methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, starch (e.g. corn starch) or dicalcium phosphate, preferably in an amount of from 0.1 to 90% by weight, e.g. 1 to 30% by weight, based on the total weight of the composition.
  • a binder e.g. microcrystalline cellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose is used, it is preferably included in an amount of 1 to 8%, e.g.
  • a binder increases the granule strength of the formulation, which is particularly important for fine granulations.
  • Microcrystalline cellulose and methylcellulose are particularly preferred where a high tablet hardness and/or longer disintegration time is required. Hydroxypropyl cellulose is preferred where faster distintegration is required.
  • xylitol may also be added as an additional binder, for example in addition to microcrystalline cellulose, e.g. in an amount up to 20% by weight of the sugar alcohol, e.g. xylitol.
  • the composition further comprises a stabiliser, preferably glycine HCl or sodium bicarbonate.
  • the stabiliser may be present in an amount of e.g. 0.1 to 30%, preferably 1 to 20% by weight.
  • compositions may be in the form of a powder, granule or pellets or a unit dosage form, for example as a tablet or capsule.
  • compositions of the present invention are well-adapted for encapsulation into an orally administrable capsule shell, particularly a hard gelatin shell.
  • compositions may be compacted into tablets.
  • the tablets may optionally be coated, for instance with talc or a polysaccharide (e.g. cellulose) or hydroxypropylmethylcellulose coating.
  • each unit dosage will suitably contain 0.5 to 10 mg of the S1P receptor agonist.
  • compositions of the invention may show good stability characteristics as indicated by standard stability trials, for example having a shelf life stability of up to one, two or three years, and even longer. Stability characteristics may be determined, e.g. by measuring decomposition products by HPLC analysis after storage for particular times, at particular temperatures, e.g. 20°, 400 or 60° C.
  • compositions of the present invention may be produced by standard processes, for instance by conventional mixing, granulating, sugar-coating, dissolving or lyophilizing processes. Procedures which may be used are known in the art, e.g. those described in L. Lachman et al. The Theory and Practice of Industrial Pharmacy, 3rd Ed, 1986, H. Sucker et al, Pharmazeutician Technologie, Thieme, 1991, Hagers Handbuch der pharmazeutica fürtechnik, 4th Ed. (Springer Verlag, 1971) and Remington's Pharmaceutical Sciences, 13th Ed., (Mack Publ., Co., 1970) or later editions.
  • the present invention relates to a process for producing a pharmaceutical composition, comprising:
  • the S1P receptor agonist e.g. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, hydrochloride
  • the mixing step (a) may suitably comprise blending the S1P receptor agonist and the sugar alcohol, e.g. mannitol in any suitable blender or mixer for e.g. 100 to 400 revolutions.
  • the process may be carried out by dry mixing the components.
  • the milling step (b) may suitably comprise passing the mixture obtained in (a) through a screen, which preferably has a mesh size of 400 to 500 ⁇ m.
  • Process step (a) may comprise the step of mixing the total amount of S1P receptor agonist at first with a low amount of sugar alcohol, e.g. from 5 to 25% by weight of the total weight of sugar alcohol, in order to form a pre-mix. Subsequently the remaining amount of sugar alcohol is added to the pre-mix.
  • Step (a) may also comprise the step of adding a binder solution, e.g. methylcellulose and/or xylitol, e.g. an aqueous solution, to the mixture. Alternatively the binder is added to the mix dry and water is added in the granulation step.
  • a binder solution e.g. methylcellulose and/or xylitol, e.g. an aqueous solution
  • the milled mixture obtained in (b) may optionally be blended once more before mixing with the lubricant.
  • the lubricant e.g. magnesium stearate
  • the S1P receptor agonist is preferably first dry-mixed with the desired sugar alcohol, e.g. mannitol, and the obtained sugar alcohol/S1P receptor agonist mixture is then dry-mixed with a binder such as hydroxypropyl cellulose or hydroxypropylmethyl cellulose. Water is then added and the mixture granulated, e.g. using an automated granulator. The granulation is then dried and milled.
  • a binder such as hydroxypropyl cellulose or hydroxypropylmethyl cellulose.
  • an additional amount of binder may be added in step (c) to the mixture obtained in (b).
  • the process may comprise a further step of tabletting or encapsulating the mixture obtained in (c), e.g. into a hard gelatin capsule using an automated encapsulation device.
  • the capsules may be coloured or marked so as to impart an individual appearance and to make them instantly recognizable.
  • the use of dyes can serve to enhance the appearance as well as to identify the capsules.
  • Dyes suitable for use in pharmacy typically include carotinoids, iron oxides, and chlorophyll.
  • the capsules of the invention are marked using a code.
  • compositions of the present invention are useful, either alone or in combination with other active agents, for the treatment and prevention of conditions e.g. as disclosed in U.S. Pat. No. 5,604,229, WO 97/24112, WO 01/01978, U.S. Pat. No. 6,004,565, U.S. Pat. No. 6,274,629 and JP-14316985, the contents of which are incorporated herein by reference.
  • compositions are useful for:
  • organ or tissue transplant rejection for example for the treatment of the recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants, and the prevention of graft-versus-host disease, such as sometimes occurs following bone marrow transplantation; particularly in the treatment of acute or chronic allo- and xenograft rejection or in the transplantation of insulin producing cells, e.g. pancreatic islet cells;
  • autoimmune disease e.g. multiple sclerosis, arthritis (for example rheumatoid arthritis), inflammatory bowel disease, hepatitis, etc.;
  • the present invention provides:
  • composition as defined above for use in treating or preventing a disease or condition as defined above.
  • a method of treating a subject in need of immunomodulation comprising administering to the subject an effective amount of a composition as defined above.
  • a method of treating or preventing a disease or condition as defined above comprising administering to the subject a composition as defined above.
  • Micronized Compound A e.g. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, hydrochloride salt (FTY720), is screened and 116.7 g of the screened compound is mixed with 9683.3 g mannitol (Parteck M200 from E. Merck). The mixture is then milled in a Frewitt MGI device (Key International Inc. USA) using a 30 mesh screen. Magnesium stearate is screened using a 20 mesh screen and 200 g of the screened compound blended with the FTY720/mannitol mixture to produce a product composition.
  • FTY720 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, hydrochloride salt
  • the product composition is then compacted on a tablet press using a 7 mm die to form 120 mg tablets, each containing: Compound A, e.g. FTY720* 1.4 mg Mannitol M200 116.2 mg Magnesium stearate 2.4 mg Total 120 mg *1 mg of Compound A in free form is equivalent to 1.12 mg of FTY720.
  • Compound A e.g. FTY720* 1.4 mg Mannitol M200 116.2 mg
  • Total 120 mg *1 mg of Compound A in free form is equivalent to 1.12 mg of FTY720.
  • example 2 the process of example 1 is repeated except that the magnesium stearate is replaced by Cutina® (hydrogenated castor oil).
  • Cutina® hydrogenated castor oil
  • Compound A e.g. FTY720, and mannitol (Parteck M200 from E. Merck) are each screened separately using an 18 mesh screen.
  • 1.9 g screened FTY720 is mixed with 40 g screened mannitol for 120 revolutions in a blender at 32 rpm. The FTY720/mannitol mixture is then screened through a 35 mesh screen.
  • the screened FTY720/mannitol mixture is added to a granulator along with a further 340.1 g mannitol and 12 g hydroxypropylcellulose.
  • the mixture is mixed for 3 minutes. Water is then added at a rate of 100 ml/minute and the mixture granulated for 2 minutes. The granulation is transferred into a tray dryer and dried at 50° C. for 150 minutes.
  • the mixture is then milled in a Frewitt MGI device using a 35 mesh screen.
  • Magnesium stearate is screened and 6 g of the screened compound is blended for 90 revolutions at 32 rpm with the FTY720/mannitol mixture to produce a product composition showing a substantially uniform distribution of the S1P receptor agonist throughout the mannitol in the blend.
  • each capsule contains: FTY720* 0.56 mg Mannitol M200 114.04 mg Hydroxypropylcellulose 3.6 mg Magnesium stearate 1.8 mg Total 120 mg
  • example 3 the process of example 3 is repeated except that the magnesium stearate is replaced by Cutina® (hydrogenated castor oil).
  • Cutina® hydrogenated castor oil
  • Micronized Compound A e.g. FTY720
  • FTY720 is screened using a 400 ⁇ m (40 mesh) screen.
  • 58.35 g of the screened compound is mixed with 4841.65 g mannitol (Parteck M200 from E. Merck) in a 25 L Bohle bin blender for 240 blending revolutions.
  • the mixture is then milled in a Frewitt MGI device using a 400 ⁇ m mesh screen, and the milled mixture is blended once more.
  • Magnesium stearate is screened and 100 g of the screened compound is blended with the FTY720/mannitol mixture to produce a product composition showing a substantially uniform distribution of the S1P receptor agonist throughout the mannitol in the blend.
  • the product composition is then filled into size 3 hard gelatin shells on an Hoflinger & Karg 400 encapsulation device. 120 mg of the product composition is added to each capsule. Therefore each capsule contains: FTY720* 1.4 mg Mannitol M200 116.2 mg Magnesium stearate 2.4 mg Total 120 mg
  • capsules are manufactured using the components and in the amounts as described in Example 6a, but the FTY720 is first mixed with 14 mg mannitol (before screening). This mixture is then screened as described above. The screened mixture is then blended with the remaining mannitol and the magnesium stearate is added, followed by additional blending and filling into capsules.
  • capsules are prepared as described in example 6, except that each capsule contains each component in the following amounts:
  • Example 7 Example 8 FTY720* 2.8 mg 5.6 mg Mannitol M200 114.8 mg 112 mg Magnesium stearate 2.4 mg 2.4 mg Total 120 mg 120 mg
  • capsules are prepared as described in examples 6 to 8, except that the magnesium stearate is replaced in each case by Cutina® (hydrogenated castor oil).
  • Cutina® hydrogenated castor oil
  • capsules or tablets are prepared as described in examples 1 to 11, except that FTY720 is replaced in each case by 2-amino-2- ⁇ 2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl ⁇ propane-1,3-diol hydrochloride.
  • Capsules containing the following ingredients are prepared, by weighing each component and mixing in a mortar, then filling into capsules:
  • Example 23 Example 24 FTY720 5 mg 1 mg D-mannitol 83.7 mg 117 mg Corn starch 24 mg — Avicel ® PH101 12 mg — Hydroxypropylcellulose 0.3 mg 7 mg Talc 3 mg 3 mg Lubri wax ® 101 2 mg 2 mg Total 130 mg 130 mg
  • Example 25 Example 26
  • Example 27 FTY720 5 g 10 g 100 g D-mannitol 991 g 986 g 897 g Methylcellulose SM-25 4 g 4 g 3 g Total 1000 g 1000 g 1000 g
  • the FTY720 and a proportion of the D-mannitol equal to twice the weight of the FTY720 are mixed in a Microspeed Mixer MS-5 type (Palmer, USA) for 2 minutes at 1200 rpm. The remaining D-mannitol is added to the mixture and mixed for another 2 minutes.
  • 80 or 60 milliliters of 5% methylcellulose SM-25 solution is supplied from a hopper and granulated under the same conditions.
  • the mixture is extruded through a screen with 0.4 mm apertures using an extruder RG-5 type.
  • the extruded material is dried at 65° C. by a fluidized-bed granulator STREA I Type (Patheon, Canada) and then sieved through a 24 mesh sieve. Fine particles which pass through a 60 mesh sieve are removed.
  • the obtained fine granules are filled Into capsules by a Zuma capsule-filling machine (100 mg per capsule).
  • Tablets containing the following ingredients are produced: Example Example Example Example 28 29 30 31 FTY720 1 1 1 1 D-mannitol 62.3 62.3 62.0 62.0 Xylitol* 26.7(5.4) 26.7(5.4) 26.6 26.6 Methylcellulose — — 0.4 0.4 Microcrystalline 24.0 — 24.0 — cellulose Low-substituted — 24.0 — 24.0 Hydroxypropylcellulose Hydrogenated oil 6.0 6.0 6.0 6.0 Total 120.0 120.0 120.0 120.0 *The amount of xylitol indicated in brackets was used as a binder.
  • FTY720, D-mannitol and xylitol are placed in a fluid-bed granulator (MP-01 model, Powrex), mixed for five minutes, and granulated under spray of binder solution, followed by drying till the exhaust temperature reaches 40° C.
  • the granulation conditions are as shown below.
  • Dried powder is passed through a 24-mesh sieve, added to the specified amount of filler and lubricant, and mixed in a mixer (Tubular Mixer, WAB) for three minutes to make the powder for compression.
  • a mixer Trobular Mixer, WAB
  • the resulting powder is compressed by a tabletting machine (Cleanpress correct 12 HUK, Kikushui Seisakusho) with a punch of 7 mm I.d. ⁇ 7.5 mm R at a compression force of 9800 N.
  • a tabletting machine (Cleanpress correct 12 HUK, Kikushui Seisakusho) with a punch of 7 mm I.d. ⁇ 7.5 mm R at a compression force of 9800 N.
  • Granulation Conditions Item Setting Charge-in amount 1170 g Volume of intake-air 50 m 3 /min Temperature of intake-air 75° C. Flow rate of spray solution 15 mL/min Spray air pressure 15 N/cm 2 Spray air volume 30 L/min Volume of binder solution 351 mL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US10/552,005 2003-04-08 2004-04-06 Organic compounds Abandoned US20060275357A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US10/552,005 US20060275357A1 (en) 2003-04-08 2004-04-06 Organic compounds
US12/189,323 US8324283B2 (en) 2003-04-08 2008-08-11 Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
US12/191,098 US20090203798A1 (en) 2003-04-08 2008-08-13 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol
US12/987,726 US20110105620A1 (en) 2003-04-08 2011-01-10 Organic compounds
US13/721,278 US20130108675A1 (en) 2003-04-08 2012-12-20 Organic compounds
US14/027,943 US20140011885A1 (en) 2003-04-08 2013-09-16 Organic Compounds
US14/285,808 US20140255497A1 (en) 2003-04-08 2014-05-23 Organic Compounds
US15/634,579 US20170290787A1 (en) 2003-04-08 2017-06-27 Organic Compounds
US16/274,357 US20190175527A1 (en) 2003-04-08 2019-02-13 Organic compounds
US16/839,703 US20200237690A1 (en) 2003-04-08 2020-04-03 Organic compounds
US17/501,173 US20220031609A1 (en) 2003-04-08 2021-10-14 Organic compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds
US10/552,005 US20060275357A1 (en) 2003-04-08 2004-04-06 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/003656 A-371-Of-International WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/189,323 Division US8324283B2 (en) 2003-04-08 2008-08-11 Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
US12/191,098 Continuation US20090203798A1 (en) 2003-04-08 2008-08-13 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol

Publications (1)

Publication Number Publication Date
US20060275357A1 true US20060275357A1 (en) 2006-12-07

Family

ID=32326722

Family Applications (11)

Application Number Title Priority Date Filing Date
US10/552,005 Abandoned US20060275357A1 (en) 2003-04-08 2004-04-06 Organic compounds
US12/189,323 Expired - Fee Related US8324283B2 (en) 2003-04-08 2008-08-11 Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
US12/191,098 Abandoned US20090203798A1 (en) 2003-04-08 2008-08-13 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol
US12/987,726 Abandoned US20110105620A1 (en) 2003-04-08 2011-01-10 Organic compounds
US13/721,278 Abandoned US20130108675A1 (en) 2003-04-08 2012-12-20 Organic compounds
US14/027,943 Abandoned US20140011885A1 (en) 2003-04-08 2013-09-16 Organic Compounds
US14/285,808 Abandoned US20140255497A1 (en) 2003-04-08 2014-05-23 Organic Compounds
US15/634,579 Abandoned US20170290787A1 (en) 2003-04-08 2017-06-27 Organic Compounds
US16/274,357 Abandoned US20190175527A1 (en) 2003-04-08 2019-02-13 Organic compounds
US16/839,703 Abandoned US20200237690A1 (en) 2003-04-08 2020-04-03 Organic compounds
US17/501,173 Abandoned US20220031609A1 (en) 2003-04-08 2021-10-14 Organic compounds

Family Applications After (10)

Application Number Title Priority Date Filing Date
US12/189,323 Expired - Fee Related US8324283B2 (en) 2003-04-08 2008-08-11 Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
US12/191,098 Abandoned US20090203798A1 (en) 2003-04-08 2008-08-13 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol
US12/987,726 Abandoned US20110105620A1 (en) 2003-04-08 2011-01-10 Organic compounds
US13/721,278 Abandoned US20130108675A1 (en) 2003-04-08 2012-12-20 Organic compounds
US14/027,943 Abandoned US20140011885A1 (en) 2003-04-08 2013-09-16 Organic Compounds
US14/285,808 Abandoned US20140255497A1 (en) 2003-04-08 2014-05-23 Organic Compounds
US15/634,579 Abandoned US20170290787A1 (en) 2003-04-08 2017-06-27 Organic Compounds
US16/274,357 Abandoned US20190175527A1 (en) 2003-04-08 2019-02-13 Organic compounds
US16/839,703 Abandoned US20200237690A1 (en) 2003-04-08 2020-04-03 Organic compounds
US17/501,173 Abandoned US20220031609A1 (en) 2003-04-08 2021-10-14 Organic compounds

Country Status (41)

Country Link
US (11) US20060275357A1 (enrdf_load_stackoverflow)
EP (5) EP1613288B1 (enrdf_load_stackoverflow)
JP (3) JP5495467B2 (enrdf_load_stackoverflow)
KR (3) KR20050121712A (enrdf_load_stackoverflow)
CN (2) CN1767819B (enrdf_load_stackoverflow)
AR (3) AR043987A1 (enrdf_load_stackoverflow)
AT (3) ATE414508T1 (enrdf_load_stackoverflow)
AU (1) AU2004228929B2 (enrdf_load_stackoverflow)
BE (2) BE1015972A5 (enrdf_load_stackoverflow)
BR (1) BRPI0409250B8 (enrdf_load_stackoverflow)
CA (2) CA2521325C (enrdf_load_stackoverflow)
CL (2) CL2004000745A1 (enrdf_load_stackoverflow)
CY (3) CY1110260T1 (enrdf_load_stackoverflow)
DE (4) DE102004016947A1 (enrdf_load_stackoverflow)
DK (2) DK2316431T3 (enrdf_load_stackoverflow)
EC (1) ECSP056090A (enrdf_load_stackoverflow)
ES (3) ES2228282B1 (enrdf_load_stackoverflow)
FR (2) FR2854073B1 (enrdf_load_stackoverflow)
GB (1) GB2400318B (enrdf_load_stackoverflow)
GR (1) GR1005052B (enrdf_load_stackoverflow)
HR (3) HRP20100600A2 (enrdf_load_stackoverflow)
HU (2) HUE028247T2 (enrdf_load_stackoverflow)
IL (3) IL170888A (enrdf_load_stackoverflow)
IS (2) IS2682B (enrdf_load_stackoverflow)
IT (1) ITMI20040682A1 (enrdf_load_stackoverflow)
LU (1) LU91867I2 (enrdf_load_stackoverflow)
MA (1) MA27729A1 (enrdf_load_stackoverflow)
MX (1) MXPA05010860A (enrdf_load_stackoverflow)
MY (1) MY141249A (enrdf_load_stackoverflow)
NO (4) NO329332B1 (enrdf_load_stackoverflow)
NZ (3) NZ542622A (enrdf_load_stackoverflow)
PE (5) PE20150676A1 (enrdf_load_stackoverflow)
PL (2) PL1613288T3 (enrdf_load_stackoverflow)
PT (1) PT1613288E (enrdf_load_stackoverflow)
RU (5) RU2358716C2 (enrdf_load_stackoverflow)
SG (1) SG175449A1 (enrdf_load_stackoverflow)
SI (2) SI2316431T1 (enrdf_load_stackoverflow)
TN (1) TNSN05256A1 (enrdf_load_stackoverflow)
TW (1) TWI332847B (enrdf_load_stackoverflow)
WO (1) WO2004089341A1 (enrdf_load_stackoverflow)
ZA (1) ZA200507394B (enrdf_load_stackoverflow)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081685A1 (en) * 2007-03-29 2010-04-01 Daiichi Sankyo Company, Limited Pharmaceutical composition
US20120114711A1 (en) * 2009-06-18 2012-05-10 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
US8357808B2 (en) 2009-03-10 2013-01-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
US8394821B2 (en) 2009-01-13 2013-03-12 Daiichi Sankyo Company, Limited Activated blood coagulation factor inhibitor
US8404847B2 (en) 2008-12-17 2013-03-26 Daiichi Sankyo Company, Limited Method for producing diamine derivative
US8541443B2 (en) 2010-03-19 2013-09-24 Daiichi Sankyo Company, Limited Crystal of diamine derivative and method of producing same
US8901345B2 (en) 2010-07-02 2014-12-02 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
US9175012B2 (en) 2009-03-13 2015-11-03 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
US9918975B2 (en) 2010-03-19 2018-03-20 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001236A (es) * 2004-07-30 2007-03-23 Novartis Ag Formulaciones de compuestos de 2-amino-1, 3-propanodiol.
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
KR101476591B1 (ko) * 2005-09-09 2014-12-24 노파르티스 아게 자가면역성 질환의 치료
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2007149512A2 (en) 2006-06-19 2007-12-27 Proteolix, Inc. Peptide epoxyketones for pr0teas0me inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
BRPI0717570B8 (pt) * 2006-09-26 2021-05-25 Novartis Ag composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
NZ584814A (en) 2007-10-04 2012-03-30 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
KR101710845B1 (ko) * 2007-10-12 2017-02-27 노파르티스 아게 스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
NZ588505A (en) 2008-03-17 2012-09-28 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one
US20110152380A1 (en) 2008-06-20 2011-06-23 Kovarik John M Paediatric Compositions For Treating Multiple Sclerosis
JP5756749B2 (ja) * 2008-06-20 2015-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 直接圧縮性および迅速崩壊性錠剤マトリックス
RU2498636C2 (ru) * 2008-09-04 2013-11-20 Карджилл Инкорпорейтед Таблетирование эритрита
UA104600C2 (ru) 2008-10-21 2014-02-25 Онікс Терап'Ютікс, Інк. Комбинированная терапия с применением пептида эпоксикетона
PE20120012A1 (es) 2008-11-11 2012-02-02 Novartis Ag Sales de fingolimod
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CA2743232C (en) * 2008-11-11 2015-12-29 Novartis Ag Crystalline forms of fingolimod hcl
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
KR20130075723A (ko) 2010-03-01 2013-07-05 오닉스 세라퓨틱스, 인크. 면역프로테아좀 저해를 위한 화합물
US20130095177A1 (en) * 2010-04-22 2013-04-18 Ratiopharm Gmbh Method of preparing an oral dosage form comprising fingolimod
CN103458877B (zh) 2011-01-07 2016-06-08 诺华股份有限公司 免疫抑制性制剂
NO2665471T3 (enrdf_load_stackoverflow) 2011-01-19 2018-05-26
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP6370804B2 (ja) 2013-01-08 2018-08-08 パソロジカ エルエルシー 脱髄疾患の治療のための方法および組成物
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
US9629834B2 (en) * 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
MX2023008907A (es) * 2021-01-28 2023-08-09 Priothera Sas Metodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p).

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110322A (en) * 1976-07-12 1978-08-29 Akzona Incorporated Peptide derivatives and pharmaceutical compositions containing same
US7151093B2 (en) * 1999-07-12 2006-12-19 Ono Pharmaceutical Co., Ltd. Use of sphingosine 1-phosphate as active ingredient for the treatment of pulmonary fibrosis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
BR9811453A (pt) * 1997-02-27 2000-09-12 Yoshitomi Pharmaceutical Composição farmacêutica
IL155065A (en) * 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
DK1377593T3 (da) 2001-03-26 2006-04-10 Novartis Ag 2-Amino-propanolderivater
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
DE60223699T2 (de) 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
EP1575964B1 (en) 2002-01-18 2009-11-11 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110322A (en) * 1976-07-12 1978-08-29 Akzona Incorporated Peptide derivatives and pharmaceutical compositions containing same
US7151093B2 (en) * 1999-07-12 2006-12-19 Ono Pharmaceutical Co., Ltd. Use of sphingosine 1-phosphate as active ingredient for the treatment of pulmonary fibrosis

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081685A1 (en) * 2007-03-29 2010-04-01 Daiichi Sankyo Company, Limited Pharmaceutical composition
US9707296B2 (en) 2007-03-29 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition
US9149532B2 (en) 2007-03-29 2015-10-06 Daiichi Sanykyo Company, Limited Pharmaceutical composition
US8404847B2 (en) 2008-12-17 2013-03-26 Daiichi Sankyo Company, Limited Method for producing diamine derivative
US8394821B2 (en) 2009-01-13 2013-03-12 Daiichi Sankyo Company, Limited Activated blood coagulation factor inhibitor
US8357808B2 (en) 2009-03-10 2013-01-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
US9175012B2 (en) 2009-03-13 2015-11-03 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
US8449896B2 (en) * 2009-06-18 2013-05-28 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
US20120114711A1 (en) * 2009-06-18 2012-05-10 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
US9918975B2 (en) 2010-03-19 2018-03-20 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
US8541443B2 (en) 2010-03-19 2013-09-24 Daiichi Sankyo Company, Limited Crystal of diamine derivative and method of producing same
US8901345B2 (en) 2010-07-02 2014-12-02 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
US20130034603A1 (en) * 2011-08-01 2013-02-07 Julia Hrakovsky Process for preparing pharmaceutical compositions of fingolimod
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US10555902B2 (en) 2015-01-20 2020-02-11 Handa Pharmaceuticals Llc Stable fingolimod dosage forms
US10925829B2 (en) 2015-01-20 2021-02-23 Handa Neuroscience, Llc Stable solid fingolimod dosage forms

Also Published As

Publication number Publication date
IL170888A (en) 2010-06-16
US20200237690A1 (en) 2020-07-30
HRP20050886B1 (en) 2011-01-31
NO20131287L (no) 2006-01-09
PE20150676A1 (es) 2015-05-17
HK1071685A1 (en) 2005-07-29
NZ586280A (en) 2011-12-22
GR1005052B (el) 2005-11-30
AR078782A2 (es) 2011-11-30
EP2008650A2 (en) 2008-12-31
ES2556947T3 (es) 2016-01-21
AU2004228929B2 (en) 2008-02-07
US20190175527A1 (en) 2019-06-13
CY1117071T1 (el) 2017-04-05
PL1613288T3 (pl) 2009-07-31
KR20050121712A (ko) 2005-12-27
WO2004089341A1 (en) 2004-10-21
HK1155647A1 (en) 2012-05-25
RU2012148593A (ru) 2014-05-20
EP1613288B1 (en) 2008-11-19
DE202004021680U1 (de) 2010-04-22
ECSP056090A (es) 2006-03-01
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
HRP20100601A2 (hr) 2011-03-31
TWI332847B (en) 2010-11-11
BRPI0409250B1 (pt) 2017-07-11
PE20050396A1 (es) 2005-07-05
EP2316431B1 (en) 2015-09-30
KR20120101148A (ko) 2012-09-12
IL197578A (en) 2015-10-29
DK1613288T3 (da) 2009-03-23
NO334116B1 (no) 2013-12-16
DK2316431T3 (en) 2016-01-11
RU2475237C2 (ru) 2013-02-20
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
LU91867I9 (enrdf_load_stackoverflow) 2019-01-03
NO2011016I2 (no) 2012-08-27
CN101797241B (zh) 2013-03-27
US20110105620A1 (en) 2011-05-05
HRP20050886A2 (en) 2006-11-30
DE102004016947A1 (de) 2004-10-21
ATE414508T1 (de) 2008-12-15
GB2400318A (en) 2004-10-13
DE602004017847D1 (de) 2009-01-02
SI2316431T1 (sl) 2016-04-29
NZ592339A (en) 2012-09-28
IS8114A (is) 2005-11-01
FR2854073B1 (fr) 2008-03-14
MA27729A1 (fr) 2006-01-02
FR11C0036I1 (fr) 2011-10-14
PE20090743A1 (es) 2009-07-17
AR043987A1 (es) 2005-08-17
US20080311188A1 (en) 2008-12-18
AR078781A2 (es) 2011-11-30
HUE028247T2 (en) 2016-12-28
ES2228282B1 (es) 2006-02-16
EP2769713A1 (en) 2014-08-27
JP2011006461A (ja) 2011-01-13
EP1613288A1 (en) 2006-01-11
KR101367574B1 (ko) 2014-02-25
GB0407819D0 (en) 2004-05-12
CA2707750A1 (en) 2004-10-21
CA2521325A1 (en) 2004-10-21
BRPI0409250A (pt) 2006-03-28
US20140011885A1 (en) 2014-01-09
CY1110260T1 (el) 2014-04-09
CL2004000745A1 (es) 2005-02-11
NO329332B1 (no) 2010-09-27
KR20110005320A (ko) 2011-01-17
PE20130200A1 (es) 2013-03-09
CN1767819B (zh) 2010-07-28
CA2521325C (en) 2010-09-14
US20220031609A1 (en) 2022-02-03
HRP20100600A2 (hr) 2011-03-31
ITMI20040682A1 (it) 2004-07-06
DE122011100047I1 (de) 2011-12-15
RU2010147000A (ru) 2012-08-10
US20170290787A1 (en) 2017-10-12
SI1613288T1 (sl) 2009-04-30
TW200503784A (en) 2005-02-01
HK1091114A1 (en) 2007-01-12
CY2011013I2 (el) 2014-04-09
IL242037A0 (en) 2015-11-30
PT1613288E (pt) 2009-02-25
EP2319502A1 (en) 2011-05-11
CN1767819A (zh) 2006-05-03
FR2854073A1 (fr) 2004-10-29
IS2682B (is) 2010-10-15
NO20055231D0 (no) 2005-11-07
JP2004307506A (ja) 2004-11-04
AU2004228929A1 (en) 2004-10-21
US8324283B2 (en) 2012-12-04
BRPI0409250B8 (pt) 2022-01-18
ZA200507394B (en) 2007-03-28
NO20100250L (no) 2006-01-09
CY2011013I1 (el) 2014-04-09
NZ542622A (en) 2009-01-31
NO335120B1 (no) 2014-09-22
US20130108675A1 (en) 2013-05-02
EP2316431A1 (en) 2011-05-04
BE2011C030I2 (enrdf_load_stackoverflow) 2023-03-07
PE20131352A1 (es) 2013-11-14
EP2008650A3 (en) 2011-04-27
MY141249A (en) 2010-03-31
HRP20100601B1 (hr) 2016-12-02
US20140255497A1 (en) 2014-09-11
LU91867I2 (fr) 2011-11-08
JP5495467B2 (ja) 2014-05-21
JP5543298B2 (ja) 2014-07-09
HUS1100016I1 (hu) 2016-08-29
IS8885A (is) 2010-02-25
RU2010146697A (ru) 2012-05-27
SG175449A1 (en) 2011-11-28
TNSN05256A1 (en) 2007-07-10
RU2358716C2 (ru) 2009-06-20
JP2013177404A (ja) 2013-09-09
GB2400318B (en) 2005-08-10
NO2011016I1 (no) 2011-09-19
GR20040100121A (el) 2004-12-17
ES2228282A1 (es) 2005-04-01
RU2009105403A (ru) 2010-08-27
CN101797241A (zh) 2010-08-11
AT501681A1 (de) 2006-10-15
RU2005134173A (ru) 2006-09-10
IE20040246A1 (en) 2004-12-15
AT504853A2 (de) 2008-08-15
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
MXPA05010860A (es) 2006-05-25
AT501681B1 (de) 2012-04-15
RU2475236C2 (ru) 2013-02-20
US20090203798A1 (en) 2009-08-13
FR11C0036I2 (fr) 2023-12-29

Similar Documents

Publication Publication Date Title
US20220031609A1 (en) Organic compounds
AU2011205050B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2008200368B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
HK1091114B (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155650A (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155647B (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION